References
- Criscione L, deGasparo M, Bühlmayer P, et al. (1993). Pharmacological profile of valsartan: a potent, orally active, nonpeptide antagonist of the angiotensin II AT1-receptor subtype. Br J Pharmacol 110:761–71
- Dhuria S, Einolf H, Mangold J, et al. (2008). Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects. J Clin Pharmacol 53:642–53
- Gu J, Noe A, Chandra P, et al. (2010). Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi). J Clin Pharmacol 50:401–4
- He H, Tran P, Yin H, et al. (2009). Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans. Drug Metab Dispos 37:536–44
- Nodaa K, Nakayamaa K, Moddermanb J. (1996). Fate of erythritol after single oral administration to rats and dogs. Regul Toxicol Pharmacol 24:S206–13
- Lee CY, Burnett JC Jr. (2007). Natriuretic peptides and therapeutic applications. Heart Fail Rev 12:131–42
- McKeage MJ, Fong PC, Hong X, et al. (2012). Mass balance, excretion and metabolism of [14C] ASA404 in cancer patients in a phase I trial. Cancer Chemother Pharmacol 69:1145–54
- Rubattu S, Sciarretta S, Valenti V, et al. (2008). Natriuretic peptides: an update on bioactivity, potential therapeutic use, and implication in cardiovascular diseases. Am J Hypertens 21:733–41
- Taavitsainen P, Kiukaanniemi K, Pelkonen O. (2000). In vitro inhibition screening of human hepatic P450 enzymes by five angiotensin-II receptor antagonists. Eur J Clin Pharmacol 56:135–40
- Valentin J. (2007). The 2007 recommendations of the international commission on radiological protection. ICRP publication 103. Ann ICRP 37(2--4):1–332
- Vardeny O, Tacheny T, Solomon SD. (2013). First-in-class angiotensin receptor neprilysin inhibitor in heart failure. Clin Pharmacol Ther 94:445–8
- Volpe M, Rubattu S, Burnett J Jr. (2014). Natriuretic peptides in cardiovascular diseases: current use and perspectives. Eur Heart J 35:419–25
- Waldmeier F, Flesch G, Müller P, et al. (1997). Pharmacokinetics, disposition and biotransformation of [14C]-radiolabelled valsartan in healthy male volunteers after a single oral dose. Xenobiotica 27:59–71